Generali Investments Towarzystwo Funduszy Inwestycyjnych Cuts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Generali Investments Towarzystwo Funduszy Inwestycyjnych lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 8.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,150 shares of the specialty pharmaceutical company’s stock after selling 100 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Jazz Pharmaceuticals were worth $142,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of JAZZ. IFP Advisors Inc bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at $25,000. UMB Bank n.a. raised its stake in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 129 shares during the period. Itau Unibanco Holding S.A. raised its stake in shares of Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after buying an additional 172 shares during the period. GAMMA Investing LLC raised its stake in shares of Jazz Pharmaceuticals by 49.8% in the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 206 shares during the period. Finally, Venturi Wealth Management LLC raised its stake in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after buying an additional 704 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $143.27 on Friday. The stock has a 50-day moving average price of $125.87 and a 200-day moving average price of $118.62. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $8.66 billion, a P/E ratio of 20.18, a PEG ratio of 1.04 and a beta of 0.56.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several research reports. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Piper Sandler reiterated an “overweight” rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $182.47.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.